All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Breast Cancer Expert Focuses on Decoding Biomarkers

February 2nd 2023

For Kevin Kalinsky, MD, MS, director of breast medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, his work on the RxPONDER trial serves as one of a few accomplishments for which he is grateful that have impacted clinical care.

Tucatinib/Trastuzumab Combination Finds a Role in HER2+ mCRC

February 2nd 2023

John H. Strickler, MD, highlights key findings from the MOUNTAINEER trial and addresses the possibility of moving the combination up to the first line setting.

NCCN Adds Neratinib to New Metastatic Breast Cancer Guidelines

February 1st 2023

In recommendations released January 27, 2023, the National Comprehensive Cancer Network now advises physicians to consider neratinib for patients with HER2-negative metastatic breast cancer, regardless of estrogen receptor status, with activating mutations in the HER2 gene as detected by next-generation sequencing of tumor tissue or circulating tumor DNA.

Neoadjuvant Chemo Reduces 2-Year Risk for Residual, Recurrent Disease by 28% in Colon Cancer

February 1st 2023

Six weeks of preoperative oxaliplatin-fluoropyrimidine chemotherapy did not increase perioperative morbidity in patients with radiologically staged T3-4, N0-2, M0 colon cancer, according to findings from the international phase 2/3 FOxTROT trial.

FDA Grants Orphan Drug Designation to BEA-17 for Glioblastoma

February 1st 2023

The FDA has granted an orphan drug designation to BEA-17 for the treatment of patients with glioblastoma.

Mutation Status Drives PARP Inhibitor Investigation and Treatment in mCRPC

February 1st 2023

Atish D. Choudhury, MD, PhD, discussed the significance of these trials within the metastatic castration-resistant prostate cancer treatment landscape, highlighted investigative PARP inhibitor combinations, and emphasized the need for further research in this area to determine which patients are most likely to benefit from certain therapies based on their molecular profiles.

Three-Drug Combination Therapy Effective in Patients with High-Risk CLL, Trial Shows

February 1st 2023

A three-drug combination that sent chronic lymphocytic leukemia into deep remissions in a broad group of patients in a clinical trial is highly effective in patients with high-risk forms of the disease, a new, phase 2 clinical trial led by Dana-Farber Cancer Institute investigators indicates.

Remestemcel-L BLA Resubmitted to FDA for Pediatric Steroid-Refractory aGVHD

February 1st 2023

A biologics license application seeking the approval of remestemcel-L has been resubmitted to the FDA for the treatment of pediatric patients with steroid-refractory, acute graft-vs-host-disease.

Neoadjuvant Therapy Helps Shape Changing Landscape of Early-Stage NSCLC

February 1st 2023

The treatment of patients with early-stage non–small cell lung cancer is rapidly evolving across the spectrum of care, particularly in the neoadjuvant setting, where evidence in favor of systemic chemoimmunotherapy regimens is growing.

DZD1516 Plus Trastuzumab Deruxtecan Shows Preclinical Synergy in HER2+ Breast Cancer with Brain Metastases

February 1st 2023

Nicholas P. McAndrew, MD, MSCE, discusses the need for HER2-targeted TKIs specifically designed to penetrate the blood-brain barrier, updated clinical data on the safety and tolerability of DZD1516 monotherapy, and the implications of nonclinical data on DZD1516 for treating CNS metastases in HER2-positive breast cancer.

FDA Grants Orphan Drug Exclusivity to Pedmark for Prevention of Platinum-Induced Ototoxicity in Pediatric Solid Tumors

January 31st 2023

The FDA has granted orphan drug exclusivity to sodium thiosulfate injection, which is indicated to reduce the risk of platinum-induced ototoxicity in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors.

Ibrutinib Plus Chemo Induction Followed by Ibrutinib Maintenance Could Be New Standard in MCL

January 31st 2023

Martin Dreyling, MD, discusses the safety and efficacy data from the TRIANGLE study done in patients with previously untreated MCL who are younger than 66 years, and the impact of these results on the use of ASCT in this population.

Researcher Highlights Need for Improved Understanding of Prostate Basal Cell Carcinoma

January 31st 2023

Basal cell carcinoma of the prostate is a rare variant of prostate cancer so uncommon that few physicians will ever treat the disease in their careers. Only 100 or so patients have been identified in the literature compared with more than 1 million diagnoses every year for adenocarcinoma.

Pirtobrutinib’s Approval Addresses Unmet Need in MCL Treatment Paradigm

January 31st 2023

Michael L. Wang, MD, discusses the efficacy of the noncovalent BTK inhibitor pirtobrutinib, as well as safety data from the phase 1/2 BRUIN trial in mantle cell lymphoma.

Henry Ford Health + MSU Health Sciences Funds Five Cancer Research Grants to Advance Cancer Medicine, Combat Health Disparities

January 31st 2023

Henry Ford Health + Michigan State University Health Sciences announced its funding of 5 cancer research grants of up to $100,000 each. These 5 grants follow an initial wave of funding from the partnership, in which 18 pilot grants of up to $25,000 each were funded in May 2022.

Brentuximab Vedotin Plus Nivolumab/Dacarbazine/Doxorubicin Produces Promising Efficacy in Hodgkin Lymphoma

January 31st 2023

Mitul Gandhi, MD, discusses the rationale of combining brentuximab vedotin, nivolumab, dacarbazine, and doxorubicin for patients with early-stage classic Hodgkin lymphoma, the key findings from part C of the SGN35-027 trial, and the next steps for investigating this combination.

Unanswered Questions Spur Future Lung Cancer Research Efforts

January 31st 2023

Edward B. Garon, MD, MS, describes research combining angiogenesis and PD-1/PD-L1 inhibition stemming from the phase 3 IMpower150 trial in patients with metastatic nonsquamous NSCLC.

FDA Grants Breakthrough Therapy Designation for Pimicotinib in TGCT

January 30th 2023

The FDA has granted a breakthrough therapy designation to pimicotinib for the treatment of patients with tenosynovial giant cell tumor who are not amenable for surgery.

Adjuvant T-DM1 Plus Concurrent Radiation Not Associated With Increased Cardiotoxicity in HER2+ Breast Cancer

January 30th 2023

Mridula George, MD, discusses the methods used to evaluate cardiotoxicity associated with adjuvant trastuzumab emtansine plus concurrent radiation therapy, and explains implications on the use of trastuzumab emtansine plus radiation in patients with early-stage HER2-positive breast cancer.

Nanvuranlat Significantly Improves PFS in Pretreated, Advanced Biliary Tract Cancer

January 30th 2023

Nanvuranlat, a first-in-class LAT1 inhibitor, induced a statistically significant improvement in progression-free survival compared with placebo in patients with advanced, pretreated refractory biliary tract cancer.